TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8704697
Drug: Low PC
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low PC pre-chemotherapy
Study: 7491349
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (LTOT)
Study: 6432084
Drug: Dihydroergostin (DE‐145)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergostin (DE‐145) 2 mg intravenous administration
Study: 11966935
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of n-6 polyunsaturated fatty acids
Study: 8918492
Drug: 5-FU dose
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU dose intensity > 1,400 mg/m2/wk over four courses
Study: 1986658
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1
Study: 1986658
Drug: Propofol 5
Normalized name: propofol 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 5 mg.kg‐1
Study: 1986658
Drug: Thiopental 5‐7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5‐7 mg.kg‐1
Study: 6642069
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of enteric-coated erythromycin base (Ery-Max) administered twice daily for 10 days
Study: 6642069
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of enteric-coated erythromycin base (Ery-Max) administered four times daily for 10 days
Study: 6642069
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with enteric-coated erythromycin base (Ery-Max)
Study: 26897389
Drug: SMART regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART regimen (budesonide/formoterol 200/6-µg metered dose inhaler for maintenance and reliever therapy)
Study: 26897389
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (salbutamol 100 µg 1-2 actuations for symptom relief)
Study: 17498016
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (20‐25 mg x kg(‐1)) at the third hour
Study: 14634860
Drug: Maintenance iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance iron therapy (6 mg/kg per month)
Study: 14634860
Drug: Intermittent iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent iron therapy (14.4 mg/kg per month)
Study: 8403132
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (SAB) with plain 0.5% bupivacaine (15 mg) and 0.2 mg epinephrine added
Study: 8403132
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia (AEA) with the same solution alkalinized with bicarbonate
Study: 3042643
Drug: Etofenamate gel
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofenamate gel
Study: 10847536
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) treatment with a resorbable polylactic acid (PLA) barrier
Study: 26508503
Drug: Iguratimod (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iguratimod (25 mg, twice daily, orally)
Study: 18702903
Drug: Nasal douching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal douching with a 200‐mL nasal irrigation bottle (one standardized squeeze bilaterally)
Study: 9725757
Drug: lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (2 mg)
Study: 12810142
Drug: Buprenorphine 1
Normalized name: buprenorphine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 1 mg
Study: 12810142
Drug: Methadone 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 30 mg
Study: 7775634
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including placebo)
Study: 16641430
Drug: FTC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC plus CLV (200 mg FTC QD + 10 mg CLV QD)
Study: 16641430
Drug: FTC alone
Normalized name: (-)-FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC alone (200 mg FTC QD + placebo)
Study: 10370615
Drug: Stop-flow thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop-flow thoracic perfusion with systemic chemotherapy and inhalation IL-2 immunotherapy (Group B)
Study: 10370615
Drug: Stop-flow thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop-flow thoracic perfusion with systemic chemotherapy without inhalation IL-2 immunotherapy (Group A)
Study: 21610124
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin treatment
Study: 22963588
Drug: Exercise on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise on Prescription (EoP)
Study: 11380069
Drug: Reference isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference isosorbide dinitrate sublingual tablet (5 mg)
Study: 11380069
Drug: Test isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test isosorbide dinitrate sublingual tablet (5 mg)
Study: 2233904
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D)
Study: 452871
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of quinestrol (oral, one tablet once a month)
Study: 452871
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, one tablet once a month)
Study: 22018187
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg/day
Study: 6148345
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose propranolol
Study: 17241875
Drug: AT(1) receptor
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT(1) receptor antagonist losartan
Study: 17241875
Drug: AT(1) receptor
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT(1) receptor antagonist candesartan
Study: 15717509
Drug: Kinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic therapy (KT) with propofol sedation
Study: 10066989
Drug: Couples with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples with 1 drug-abusing partner (husband or wife)
Study: 10066989
Drug: Couples with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples with both partners abusing drugs
Study: 10066989
Drug: Couples with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples with 1 drug-abusing partner during and 1 year after treatment
Study: 7644246
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg, 8 mg)
Study: 973761
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in 13 patients
Study: 22776534
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg/d)
Study: 15168289
Drug: V.A.C. therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: V.A.C. therapy
Study: 15556824
Drug: High-dose adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adenosine infusion (140 microg/kg/min for 22 minutes)
Study: 15556824
Drug: Beta-endorphin bolus
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-endorphin bolus followed by infusion
Study: 15556824
Drug: Naloxone bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone bolus followed by NaCl infusion
Study: 15556824
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl bolus for 2 minutes followed by NaCl infusion for 15 minutes)
Study: 31041523
Drug: CXL combined
Normalized name: CXL-1020
DrugBank: CXL-1020 (DB15326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXL combined with antifungal medications (CXL‐M)
Study: 31041523
Drug: Antifungal medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal medications alone (M)
Study: 19262495
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg day(-1) increased to 10 mg day(-1))
Study: 18690917
Drug: 5‐HT and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT and NA reuptake inhibitors (e.g., duloxetine)
Study: 9264050
Drug: Estazolam tablets
Normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam tablets (reference formulation, ESILGAN)
Study: 8319321
Drug: Nuelin SA
Normalized name: Nuelin S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus Nuelin liquid (non-sustained-release theophylline) 100 mg, 200 mg, or 300 mg
Study: 8319321
Drug: Nuelin SA
Normalized name: Nuelin S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus placebo
Study: 3621870
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg b.w. of TGLVP
Study: 15983221
Drug: Ruboxistaurin (RBX)
Normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruboxistaurin (RBX) 32 mg/day
Study: 12857503
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg esmolol combined with 2 microg/kg fentanyl (Group D)
Study: 6367947
Drug: S1: CYVADIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1: CYVADIC (combination chemotherapy with cyclophosphamide, vincristine, Adriamycin, and DTIC administered simultaneously every 4 weeks)
Study: 6367947
Drug: S2: ADIC-CYV
Approvals — FDA: no, EMA: no, PMDA: no
Description: S2: ADIC-CYV (pairs of drugs administered alternating at 4 weekly intervals)
Study: 28265715
Drug: Suvorexant 40/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 40/30 mg
Study: 27397664
Drug: Suvorexant 20/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 20/15 mg
Study: 15627725
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leptin (4 microg ml(‐1) kg(‐1) body weight)
Study: 7560254
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg every 12 hours (n = 12)
Study: 7560254
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg every 12 hours
Study: 7560254
Drug: Warfarin daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin daily for 14 days
Study: 2182370
Drug: No endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endoscopic therapy (Control)
Study: 31154289
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg, s.c., weekly) + Methotrexate (7.5-15 mg, p.o., weekly)
Study: 31154289
Drug: Monotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy group (Etanercept)
Study: 28060936
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly (RJ) 1200 mg/tablet, six tablets daily for 8 weeks
Study: 30501611
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with 0.1 mg/kg dexamethasone
Study: 20487046
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Study: 19013011
Drug: Dutasteride monotherapy
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride monotherapy
Study: 23234237
Drug: Multifaceted educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted educational intervention for GPs on performing a narrative doctor-patient dialogue and medication review.
Study: 16705491
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for 4 hours/week for two weeks after standard job search assistance for two weeks
Study: 14617595
Drug: Remifentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil with morphine
Study: 9184402
Drug: PEG-Hirudin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Hirudin 0.05 to 0.6 mg/kg subcutaneous doses
Study: 9184402
Drug: PEG-Hirudin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Hirudin 0.2 to 0.4 mg/kg once daily subcutaneous for five days
Study: 9184402
Drug: PEG-Hirudin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Hirudin 0.3 mg/kg i.v. bolus followed by daily s.c. injections
Study: 8264145
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg/day, increasing to 20 to 40 mg/day as required)
Study: 3987180
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine infusion (4.5 mg in 45 minutes)
Study: 26460743
Drug: Delayed loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loaded 1P implants
Study: 22864465
Drug: Creatine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (5 g/day)
Study: 16312177
Drug: FCT SQV
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCT SQV (two 500 mg tablets)
Study: 16312177
Drug: HC SQV
Normalized name: Casporyn HC
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HC SQV (five 200 mg capsules)
Study: 12732885
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) CSA
Study: 8733205
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment specificity and high delta sleep ratio
Study: 8733205
Drug: Low treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low treatment specificity and low delta ratio
Study: 26434752
Drug: Pharmacist involvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist involvement (face-to-face medication reconciliation, patient-specific pharmaceutical care plan, discharge counseling, postdischarge phone calls on days 3, 14, and 30)
Study: 20370970
Drug: Cognitive restructuring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive restructuring and/or exposure therapy
Study: 9412547
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg)
Study: 7862229
Drug: Enoxaparin at
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin at a dose of 0.5 mg/kg (50 U1 Anti‐Xa/kg)
Study: 15795700
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid)
Study: 8953674
Drug: alpha-streptococci spray
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-streptococci spray treatment for at least 5 days
Study: 30877484
Drug: Duloxetine 30-60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30-60 mg per day for 4 weeks
Study: 30877484
Drug: Pregabalin 75-150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75-150 mg per day for 4 weeks
Study: 23797771
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CT)
Study: 6451235
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg daily)
Study: 20703230
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg per day)
Study: 20703230
Drug: Imidapril (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (2.5-10 mg per day) added to valsartan (160 mg per day)
Study: 9803047
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) oxycodone 15 mg four times daily
Study: 9803047
Drug: Both CR
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CR and IR oxycodone
Study: 8919986
Drug: Cumulative dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dosage method (group I, 33 patients)
Study: 25673441
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (four-drug FDC)
Study: 25673441
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (two-drug FDC)
Study: 25673441
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (two-drug FDC)
Study: 25673441
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D (two-drug FDC)
Study: 19075260
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg weekly
Study: 2612203
Drug: Amoxycillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin plus clavulanic acid (250 or 500 mg amoxycillin and 62.5 or 125 mg clavulanic acid) 3-times daily
Study: 23757427
Drug: Closed-loop (CL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop (CL) insulin delivery
Study: 17482982
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (3 mg/kg per day)
Study: 11675958
Drug: Arotinolol 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol 10-20 mg twice daily for 4 weeks
Study: 23086524
Drug: Rapid weight
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid weight loss (RWL) preparation with very low calorie diet
Study: 11095450
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) at a mean dose of 6.7 microg/kg x day (1.6 IU/day)
Study: 8036599
Drug: Prospidin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospidin (total dose 3.0‐9.8 g)
Study: 27425565
Drug: Strong Minds
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong Minds program (acceptance and commitment therapy combined with positive psychology)
Study: 3068300
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg q.i.d.)
Study: 23955106
Drug: d-chlorpheniramine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-chlorpheniramine 4 mg
Study: 21422197
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration in women with hypothalamic amenorrhea
Study: 2842144
Drug: Flumazenil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.2 mg)
Study: 17275695
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin administration (0.6 mg)
Study: 11488317
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg inhaled salbutamol
Study: 11514686
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg inhaled salbutamol
Study: 7512124
Drug: Growth factors
Normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factors (GFs) including G-CSF (7.5 micrograms/kg/d) and GM-CSF (2.5 micrograms/kg/d) administered as a 2-hour intravenous infusion twice per day until neutrophil count > 1,500/microL
Study: 3948703
Drug: Indoramin (0.2‐0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (0.2‐0.4 mg/kg bodyweight)
Study: 20196974
Drug: 6.6 g
Normalized name: FERROUS SULFATE 76.6 g in 454 g TOPICAL POWDER [Hemostat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6 g marine n‐3 PUFA/day
Study: 20196974
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g marine n‐3 PUFA/day
Study: 20196974
Drug: 6.6 g
Normalized name: FERROUS SULFATE 76.6 g in 454 g TOPICAL POWDER [Hemostat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6 g olive oil (control)
Study: 15179022
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75-150 mg)
Study: 9302488
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (5 g creatine plus 1 g glucose X 5 doses daily for 7 days)
Study: 9302488
Drug: Placebo (Pl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pl) treatment (6 g glucose X 5 doses daily for 7 days)
Study: 9302488
Drug: Placebo (Pl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pl) treatment
Study: 8171738
Drug: IL-2 subcutaneous
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 subcutaneous therapy (3 million IU twice/daily for 5 days/week for 6 weeks)
Study: 8171738
Drug: IL-2 subcutaneous
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 subcutaneous therapy
Study: 31177888
Drug: 24-h urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h urine protein excretion
Study: 16420567
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of rFVIIa (90 microg kg(‐1), repeated every 3 h)
Study: 16420567
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of rFVIIa (270 microg kg(‐1), single dose)
Study: 1789830
Drug: Intravenous rehydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rehydration therapy